Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cobimetinib in combination with atezolizumab, with/without vemurafenib, for BRAFV600 wild-type and BRAFV600 mutation-positive melanoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Metastases
• Melanoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-02-08